Nang Kuang Pharmaceutical Co (1752) Fair Value & Analysis
Healthcare · TW · Market cap 3.2B TWD
Fair value as of: Jul 21, 2026
From 25 valuation models · updated 21 days ago
Share price +0.3% over the past month.
A solid business, screening 40% undervalued on our models.
What matters now
- Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (28.52 TWD to 59.14 TWD) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.
How to read this chart
60‑month range 26.97 TWD – 3,837 TWD · fair‑value band 28.52 TWD – 59.14 TWD · the 31.90 TWD price screens below the 44.52 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.
Analysis
Nang Kuang Pharmaceutical Co (1752) currently trades at 31.90 TWD, while our model-based Fair Value estimate is 44.52 TWD, implying the stock looks roughly 39.6% undervalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Nang Kuang Pharmaceutical Co generated revenue of 2.1B TWD at a net margin of 9.7%. Revenue declined 8.6% year over year. It earns a return on equity of 8.7%. Net debt stands at 310M TWD. Fundamentals as of Jul 21, 2026
Our scenario range runs from 28.52 TWD (bear case) to 59.14 TWD (bull case); at 31.90 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 40%, 1752 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (44.04 TWD) versus Dividend Discount (10.55 TWD). Highest evidence: Growth DCF (80).
Notify me when 1752 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 62 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Nang Kuang Pharmaceutical Co., Ltd. manufactures, processes, trades in, imports, and exports pharmaceuticals and medical devices in Taiwan, China, Japan, the United States, and internationally.
Full company description
Nang Kuang Pharmaceutical Co., Ltd. manufactures, processes, trades in, imports, and exports pharmaceuticals and medical devices in Taiwan, China, Japan, the United States, and internationally. The company offers ready to use injections, such as prefilled syringe injections and premixed IV infusions; anti-aging and preventive medicines; chemotherapy and oncology products; and non-PVC IV infusion. It also provides various products in the areas of cardiovascular, gastrointestinal, nervous, musculo-skeletal, and respiratory system, as well as in alimentary and metabolism, blood, antineoplastic and immunomodulatory, dermatological, genito-urinary and sex hormone, systemic hormone and antibacterial, cosmetics, and hospital solutions. In addition, the company is involved in trading of pharmaceuticals. Nang Kuang Pharmaceutical Co., Ltd. was founded in 1963 and is headquartered in Tainan City, Taiwan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Nang Kuang Pharmaceutical Co reported revenue of 2.2B TWD in FY2025 versus 1.8B TWD in FY2021, a compound +5.0%/yr. Reported net income was 244M TWD in FY2025, compounding +5.6%/yr from FY2021.
of which total revenue +4.6 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 1752: get an alert when its fair value changes →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Nang Kuang Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Nang Kuang Pharmaceutical Co (1752) overvalued or undervalued?
What is the fair value of 1752?
What is the quality score of 1752?
What is the revenue of Nang Kuang Pharmaceutical Co (1752)?
What is the net profit margin of 1752?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Nang Kuang Pharmaceutical Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.